Papers
8
Total Citations
97
H-Index
5
About
Donald B. Fuller is a radiation oncologist whose career has centered on advancing stereotactic body radiation therapy (SBRT) for prostate cancer, with particular emphasis on robotic radiosurgery systems and their clinical optimization. His most significant contribution has been demonstrating the long-term efficacy and safety of hypofractionated, "HDR-like" prostate SBRT through rigorous multi-institutional clinical trials. Fuller's landmark prospective Phase II trial, enrolling 259 patients across 14 institutions, generated foundational 5- and 10-year outcome data at a time when long-term prostate SBRT evidence remained sparse, helping legitimize this approach in community treatment settings. His work integrating dynamic gadolinium-enhanced perfusion MRI to monitor treatment response (36 citations) introduced an important imaging framework for evaluating radiotherapy effectiveness in prostate cancer. Fuller has also investigated quality-of-life outcomes, identifying patient and dosimetric predictors of genitourinary and bowel toxicity following SBRT, directly informing treatment planning decisions. More recently, his research has explored whether treatment de-intensification is feasible for unfavorable intermediate-risk subgroups, reflecting a commitment to precision-driven care. Across his published work, Fuller has accumulated over 95 citations, contributing meaningfully to the evidence base that has helped establish prostate SBRT as a mainstream treatment option.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8